Copyright © 1996, 1997, 2001 by Galen Daryl Knight and VitaleTherapeutics, Inc.

The VitaleTheine Modulators and Related Compounds

Certain vitaletheine modulators have been shown to be between 70 and 100% effective in producing lifetime cure rates in mice bearing uniformly fatal tumors (melanoma and myeloma). In addition, the vitaletheine modulators (when fully configured with functional receptors and complementary compounds) can be thought of as simultaneously being both, the "hair trigger" and the "Achilles' heel", for immune responses, especially the antibody-mediated (humoral) response. Given the proper "environment" to operate effectively, this system probably constitutes one of our best defenses against disease.

In the first of the two Cancer Research articles describing these and related compounds, it was proposed that the vitaletheine modulators may require activation to the sulfenic acid, either by oxidation or through rearrangement of a benzyl derivative. Recent evidence in the treatment of cancer seems to support this hypothesis. Although neither regimen has been optimized, the benzyl derivative appears to be more effective than vitalethine in treating melanoma, especially when dead tumor cells are also administered to mice bearing uniformly fatal melanoma.

Structural similarities with a variety of other compounds known to stimulate the immune system (or to have anti-tumor, anti-autoimmune, and anti-histamine activity) predict applications for the vitaletheine modulators in a variety of problematic diseases. Among the Patents that have issued on the use of vitaletheine modulators in cell culture and for the treatment of cancer, the US Patent is the best source for additional chemical information about these compounds. Additional chemical information and tips on synthesis are provided in this Web Site and will be updated as information becomes available.


Home Overview People Journal Nutrition
WWW Links Outline e-mail us